Please login to the form below

Not currently logged in
Email:
Password:

S-A invests €350m in vaccine facility

Leading vaccine manufacturer sanofi-aventis is to construct a new manufacturing centre in Neuville-sur-Saône, France

Leading vaccine manufacturer sanofi-aventis is to construct a new manufacturing centre in Neuville-sur-Saône, France.

The new centre, near to Lyon, will come under the remit of the group's vaccine division, Sanofi Pasteur and employ 200 people. The facility will produce 100 million doses of the novel dengue fever vaccine, which is currently under development, and expects to be operational by 2013.

"This new vaccine production centre is the largest investment ever made by sanofi-aventis. It illustrates our commitment to providing solutions to unmet medical needs such as dengue, a disease that potentially puts almost half of the world's population at risk," said Christopher A Viehbacher, CEO of sanofi-aventis.

He went on to say that, including this latest investment, sanofi-aventis has invested over €1bn in vaccine production in France since 2005.

The French company is keen to respond to increasing global health needs through innovation. Earlier this month, sanofi-aventis announced it has invested almost €200m to convert its pharmaceutical production site at Vitry-sur-Seine in France to produce monoclonal antibodies.

13th May 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Adelphi Research UK

Adelphi Research UK is a healthcare insight partner. We uniquely blend robust market research with a consultancy approach, to guide...

Latest intelligence

Erik
A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018
...

Infographics